94 related articles for article (PubMed ID: 9099167)
1. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R
CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
[TBL] [Abstract][Full Text] [Related]
4. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials.
Smith PK; Datta SK; Muhlbaier LH; Samsa G; Nadel A; Lipscomb J
Ann Thorac Surg; 2004 Feb; 77(2):635-42; discussion 642-3. PubMed ID: 14759451
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial.
Cohen DJ; Murphy SA; Baim DS; Lavelle TA; Berezin RH; Cutlip DE; Ho KK; Kuntz RE;
J Am Coll Cardiol; 2004 Nov; 44(9):1801-8. PubMed ID: 15519010
[TBL] [Abstract][Full Text] [Related]
11. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
12. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
van Hout BA; Simoons ML
Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
[TBL] [Abstract][Full Text] [Related]
14. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease.
Hlatky MA; Boothroyd DB; Melsop KA; Brooks MM; Mark DB; Pitt B; Reeder GS; Rogers WJ; Ryan TJ; Whitlow PL; Wiens RD
Circulation; 2004 Oct; 110(14):1960-6. PubMed ID: 15451795
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Fidan D; Unal B; Critchley J; Capewell S
QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
[TBL] [Abstract][Full Text] [Related]
16. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
Johannesson M
Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry.
Ademi Z; Reid CM; Hollingsworth B; Stoelwinder J; Steg PG; Bhatt DL; Vale M; Liew D;
Clin Ther; 2011 Oct; 33(10):1456-65. PubMed ID: 21982384
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
19. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
[TBL] [Abstract][Full Text] [Related]
20. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
